ImmunityBio (IBRX) said Wednesday it has received the US Food and Drug Administration's authorization for an expanded access program to provide recombinant Bacillus Calmette-Guerin, addressing the nationwide shortage of TICE BCG for bladder cancer treatment.
The alternative BCG, developed by the Serum Institute of India, has performed well in European trials for non-muscle invasive bladder cancer, exhibiting strong immunogenicity and enhanced safety over previous strains.
ImmunityBio said that rBCG supplies are now available, with shipments starting immediately through an FDA Expanded Access Program.
Shares of ImmunityBio were up more than 8% in recent Wednesday trading.
Price: 3.62, Change: +0.27, Percent Change: +8.06
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.